Collegium Pharmaceutical：疼痛管理產生的現金流正推動 ADHD 領域的重新估值 (NASDAQ:COLL)
· seekingalpha.com
Collegium Pharma (COLL) 透過 AZSTARYS 轉型為中樞神經系統 (CNS)/ADHD 成長平台，瞄準 2026 年營收與 EBITDA 的成長空間；目前股價看似被低估——立即閱讀。
I have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and in...